[go: up one dir, main page]

EP0738143A1 - Curcumine, ses analogues et leurs nouvelles utilisations - Google Patents

Curcumine, ses analogues et leurs nouvelles utilisations

Info

Publication number
EP0738143A1
EP0738143A1 EP95907307A EP95907307A EP0738143A1 EP 0738143 A1 EP0738143 A1 EP 0738143A1 EP 95907307 A EP95907307 A EP 95907307A EP 95907307 A EP95907307 A EP 95907307A EP 0738143 A1 EP0738143 A1 EP 0738143A1
Authority
EP
European Patent Office
Prior art keywords
sep
acid
curcumin
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95907307A
Other languages
German (de)
English (en)
Inventor
Bharat B. Aggarwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of EP0738143A1 publication Critical patent/EP0738143A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Nouvelles méthodes de traitement de maladies caractérisées par la prolifération pathologique de cellules, consistant à administrer à un animal une dose à efficacité pharmacologique de curcumine ou de l'un de ses analogues, nouvelle méthode d'inhibition de l'activité de la phosphorylase kinase et de la tyrosine kinase, et nouvelle méthode de traitement des maladies caractérisées par la prolifération pathologique de cellules consistant à administrer une dose à efficacité pharmacologique de flavonoïde.
EP95907307A 1994-01-06 1995-01-05 Curcumine, ses analogues et leurs nouvelles utilisations Withdrawn EP0738143A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17803394A 1994-01-06 1994-01-06
US178033 1994-01-06
US19808894A 1994-02-17 1994-02-17
US198088 1994-02-17
PCT/US1995/000104 WO1995018606A1 (fr) 1994-01-06 1995-01-05 Curcumine, ses analogues et leurs nouvelles utilisations

Publications (1)

Publication Number Publication Date
EP0738143A1 true EP0738143A1 (fr) 1996-10-23

Family

ID=26873885

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95907307A Withdrawn EP0738143A1 (fr) 1994-01-06 1995-01-05 Curcumine, ses analogues et leurs nouvelles utilisations

Country Status (6)

Country Link
EP (1) EP0738143A1 (fr)
JP (1) JPH10500657A (fr)
AU (1) AU687509B2 (fr)
CA (1) CA2180477A1 (fr)
IL (1) IL112205A0 (fr)
WO (1) WO1995018606A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116407527A (zh) * 2023-01-04 2023-07-11 河南科技大学第一附属医院 咖啡酸的应用以及用于预防和治疗口腔鳞癌的药物

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2933511B2 (ja) 1995-07-28 1999-08-16 呉羽化学工業株式会社 フェルラ酸含有ｈｓｐ４７合成抑制剤
AU713863B2 (en) * 1995-06-19 1999-12-09 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물
DE19821971C2 (de) * 1998-05-18 2003-02-06 Ulti Med Products Deutschland Arzneimittel zur Behandlung von Psoriasis oder Neurodermitis
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
AU2876000A (en) * 1999-02-10 2000-08-29 Trustees Of The University Of Pennsylvania, The Tyrosine kinase inhibitors and methods of using the same
US6653327B2 (en) 1999-04-09 2003-11-25 Sabinsa Corporation Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
ES2282101T3 (es) * 1999-04-09 2007-10-16 Sabinsa Corporation Uso de tetrahidrocurcuminoides para regular sucesos fisiologicos y patologicos en la piel y las mucosas.
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
GB0113348D0 (en) 2001-06-01 2001-07-25 Mars Uk Ltd Skin diet
US6979470B2 (en) * 2001-07-17 2005-12-27 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US7105576B2 (en) * 2002-04-24 2006-09-12 Research Development Foundation Synergistic effects of nuclear transcription factor NF-κB inhibitors and anti-neoplastic agents
US7462646B2 (en) * 2003-08-26 2008-12-09 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
PT1701941E (pt) 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
ITFI20050031A1 (it) * 2005-02-21 2006-08-22 Stefan Coccoloni Una composizione farmaceutica atta a prevenire l'invecchiamento e l'insorgere di malattie vascolari,neoplastiche,cutanee e dell'apparato pilifero
GB0505509D0 (en) * 2005-03-17 2005-04-27 Ic Innovations Ltd Compounds
WO2007098504A1 (fr) * 2006-02-24 2007-08-30 Emory University Promedicaments d'analogues de curcumine
US7250158B1 (en) 2006-03-30 2007-07-31 Conopco, Inc. Skin lightening agents, compositions and methods
BRPI0709916B8 (pt) 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
WO2008131059A2 (fr) 2007-04-17 2008-10-30 Codman & Shurtleff, Inc. Administration intranasale de curcumine en bolus de gaz d'hélium pour traiter la maladie d'alzheimer
US20100197584A1 (en) * 2007-07-27 2010-08-05 Research Foundations of the City University of- New York Use of curcumin to block brain tumor formation in mice
WO2009101263A2 (fr) 2008-02-15 2009-08-20 Novobion Oy Complexes solubles de la curcumine
NZ590372A (en) 2008-07-08 2012-09-28 Univ Texas Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
US20100286585A1 (en) 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
US11312676B2 (en) 2014-12-30 2022-04-26 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
CN105669788B (zh) * 2016-03-18 2018-11-27 昆明理工大学 一种从竹笋中提取活性化合物的方法及其应用
AU2019333119B2 (en) 2018-08-29 2025-06-05 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
WO2020239948A1 (fr) 2019-05-28 2020-12-03 Isanas Ag Agoniste du récepteur μ-opioïde à action centrale en association avec un curcuminoïde s'utilisant dans le traitement d'une tumeur du système nerveux central
US20220370385A1 (en) * 2019-09-17 2022-11-24 Enzene Biosciences Ltd. Compositions for use in inhibiting src kinase and treating and preventing associated disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3777037A (en) * 1970-09-22 1973-12-04 Us Agriculture Cinnamyl phenols useful as anti-microbial agents
JPS5419790B2 (fr) * 1973-08-25 1979-07-18
FR2492815A1 (fr) * 1980-10-23 1982-04-30 Sori Soc Rech Ind Nouveau derive d'acide cinnamoyl-cinnamique, son procede de preparation et son application en therapeutique
JPS57185219A (en) * 1981-05-12 1982-11-15 Chugai Pharmaceut Co Ltd Remedy for cancer
US4733002A (en) * 1984-05-23 1988-03-22 Green Cross Corporation Lipoxygenase inhibitor
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
IL91382A (en) * 1988-09-01 1995-06-29 Orion Yhtymae Oy Alkenyl or arylmethylene-substituted beta-diketones their preparation and pharmaceutical compositions containing them
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5238832A (en) * 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9518606A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116407527A (zh) * 2023-01-04 2023-07-11 河南科技大学第一附属医院 咖啡酸的应用以及用于预防和治疗口腔鳞癌的药物

Also Published As

Publication number Publication date
CA2180477A1 (fr) 1995-07-13
WO1995018606A1 (fr) 1995-07-13
AU1558595A (en) 1995-08-01
IL112205A0 (en) 1995-03-15
AU687509B2 (en) 1998-02-26
JPH10500657A (ja) 1998-01-20

Similar Documents

Publication Publication Date Title
AU687509B2 (en) Curcumin, analogues of curcumin and novel uses thereof
WO1995018606A9 (fr) Curcumine, ses analogues et leurs nouvelles utilisations
Kadekaro et al. α-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes
Thaloor et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin
US5541232A (en) Treatment of multidrug resistant diseases
Soter et al. Local effects of synthetic leukotrienes (LTC4, LTD4, and LTB4) in human skin
Zhou et al. Cardioprotective effect of water and ethanol extract of Salvia miltiorrhiza in an experimental model of myocardial infarction
US5871779A (en) Treatment of arthropathies with vanadate compounds or analogues thereof
Lee et al. α‐Mangostin, a novel dietary xanthone, suppresses TPA‐mediated MMP‐2 and MMP‐9 expressions through the ERK signaling pathway in MCF‐7 human breast adenocarcinoma cells
CA2377141A1 (fr) Inhibition de l'angiogenese grace a l'utilisation de curcumine et de curcuminoides
Figg et al. The pharmacokinetics of TNP‐470, a new angiogenesis inhibitor
Zhang et al. Suppressing BRD4 exhibits protective effects against vincristine-induced peripheral neuropathy by alleviating inflammation and oxidative stress
Yang et al. Cerebral ischemia/reperfusion injury and pharmacologic preconditioning as a means to reduce stroke-induced inflammation and damage
Sinch et al. Calcium glucarate prevents tumor formation in mouse skin
Satomi et al. Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor
Cuzzocrea et al. Superoxide-related signaling cascade mediates nuclear factor-κB activation in acute inflammation
Samuels et al. Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice
KR101542774B1 (ko) 리그난 유도체를 함유하는 세라마이드 대사관련 효소에 의해 매개되는 질환의 예방 또는 치료용 조성물
Bedoya et al. The role of parthenolide in intracellular signalling processes: review of current knowledge
CN100370981C (zh) 毛萼乙素在制药中的应用
Spath et al. Diethyldithiocarbamate inhibits scheduled and unscheduled DNA synthesis of rat thymocytes in vitro and in vivo—dose-effect relationships and mechanisms of action
Koçak et al. Evaluation of antiproliferative and antimetastatic effects of heparin and erythropoietin on B16f10 melanoma cell line
Pilichos et al. The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model
JP2022518128A (ja) ヒト新生児ケラチノサイト前駆細胞において免疫抑制活性を有するチロシン阻害剤
KR102387564B1 (ko) 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960711

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990803